PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

nd to a collection of information unless it contains a valid OMB control numb

Sub	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/625,073-Conf. #9446	
11	NFORMATION	l Di	SCLOSURE	Filing Date	July 22, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Mark I. Greene	
_				Art Unit	1617	
	(Use as many sheets as necessary)			Examiner Name	L. M. Williams	
Sheet	1	of	1	Attorney Docket Number	20273/100K201-US2	

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

L	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/LW	ВА	WO-01/08699-A1		THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			_
Examiner	// \\\!!!!:/ /00/00/0007\	Date	-
-xammer		50.0	
Signature	reconard williams (00/20/2001)	Considered	- 1
			_

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/S8/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are requir

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

			(
Sheet	1	of	1

•	Complete If Known
Application Number	10/625,073
Filing Date	July 22, 2003
First Named Inventor	Mark I. Greene
Art Unit	1653
Examiner Name	A. A. Mohamed
Attorney Docket Number	04040/100K201-US2

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.¹	Document Number Number-Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.	Country Code ³ -Number ⁴ -Kind Code ⁸ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WQ-00/15807-A1	03-23-2000	Halkier et al.		
/LW/	BB	WO-00/01349-A2	01-13-2000	Murali et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	// // // // // // // // // // // // //	Date
	Leonard Williams/ (08/28/2007)	
Signature	recondite villianion (corected)	Considered

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Transtation is attached.

PTC/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a coffection of information unless it displays a valid OMB control number.

Substi	Substitute for form 1449/PTO			Complete If Known		
				Application Number	Not Yet Assigned	
INI	INFORMATION DISCLOSURE			Filing Date	Concurrently Herewith	
ST	STATEMENT BY APPLICANT		First Named Inventor	Mark I. Greene		
				Art Unit	1653	
	(use as many sheets as necessary)			Examiner Name	A. Mohamed	
Sheet	1	of	3	Attorney Docket Number	4040/1K201US2	

				U.S. PA	TENT DOCUMENTS	
Examiner Initials*		Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
		No.	Number-Kind Code ² (#known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
7L\	M/	AA.	4,215,051	7/29/80	Schroeder et al.	
		AB.	4,946,778	8/7/90	Ladner et al.	
		AC.	5,470,952	11/28/95	Stahl et al.	
		AD.	5,849,865	12/15/98	Cheng et al.	
1	1	AE.	5,955,425	9/21/99	Morley et al.	
	7	AF.	5,985,832	11/16/99	Roodman et al.	
7	W	AG.	5,869,452	2/9/99	Ng et al.	

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Occument	Publication	Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т⁰		
7LW/	AH	EP 0 045 665	5/8/81			Г		
7LW/	ΑI	WO 98/53842	12/3/1998			\Box		
/I W/	AJ	WO 99/58674	11/18/99					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the application number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS		
	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
/LW/	AK	Ahmed et al., The Journal of Biological Chemistry, 250(21):8477-8482, November 1975		
L	AL	Albericio et al., Int. J. Peptide Protein Res. 26:92-97, 1985		
	AM	Anderson et al. Nature, Vol. 390, pp. 175-179, November 13, 1997		
	AN	Banner et al., Cell, 73:431-445, May 1993		
	AO	Beutler et al., Science, 264:667-668, April 1994		
	AP	Beutler et al., Annals of The New York Academy of Sciences, 730:118-133, 1994		
	AQ	Bowie et al. Science, Vol. 247, pp. 1306-1310, 1990		
	AR	Brisson et al., Nature, 310:511-514, August 1984		
	AS	Broglie et al., Science 224:838-843, May 1984		
	AT	Bucay et al., Genes Dev., 12(9):1260-1268, 1998		
	AU	Cole et al., Monoclonal Antibodies and Cancer Therapy, 77-96, January-February 1985		
	AV	Coruzzi et al., The EMBO Journal 3(8):1671-1679		
	AW Cote et al., Proc. Natl. Acad. Sci. USA, 80:2026-2030, 1983			
1/	AX	Döring et al., Molecular Immunology, 31(14):1059-1067, 1994		
V	AY	Filvaroff, Current Biology, 8:R679-682, 1998		
/LW/	AZ	Fox et al. Biochem. Biphys. Res. Comm., Vol. 276, pp. 868-872, 2000		

Examiner I	Leonard Williams/ (08/28/2007)	Date
	Leonard Williams/ (08/28/2007)	100.0
Signature	720011a1a 11111a11167 (00/20/2007)	Considered
Orginataro 1		Toomsidated

PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Sub	stitute for form 1449/PTO			Complete if Known	
				Application Number	Not Yet Assigned
11	IFORMATIO	N DI	SCLOSURE	Filing Date	Concurrently Herewith
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Mark I. Greene
				Art Unit	1653
	(use as many sheets as necessary)			Examiner Name	A. Mohamed
Sheet	2	of	3	Attorney Docket Number	4040/1K201US2

 I-46, 1975 Fuller, K., et al., "TRANCE is necessary and sufficient for osteoblastmediated activation of bone resorption in osteoclasts," <i>Database Chemical Abstracts on STN, No. 129:314804</i>, Abstract, J. Exp. Med., 1998, 188(5), 997-1001 Gruss et al., Cytokines and Molecular Therapy 1:75-105, May 1995 Gurley, et al., Molecular and Cellular Biology, 6:559-565, February 1986 Habeeb, A.F.S.A., Analytical Biochemistry, 56:60-65, 1973 Hann et al., J. Chem. Soc. Perkin Trans., 1, 307-314, 1982 Holladay et al. Tetrahedron Letters, 24(41):4401-4404, 1983 	_
bone resorption in osteoclasts," Database Chemical Abstracts on STN, No. 129:314804, Abstract, J. Exp. Med., 1998, 188(5), 997-1001 C Gruss et al., Cytokines and Molecular Therapy 1:75-105, May 1995 Gurley, et al., Molecular and Cellular Biology, 6:559-565, February 1986 E Habeeb, A.F.S.A., Analytical Biochemistry, 56:60-65, 1973 F Hann et al., J. Chem. Soc. Perkin Trans., 1, 307-314, 1982 G Holladay et al. Tetrahedron Letters, 24(41):4401-4404, 1983	
Abstract, J. Exp. Med., 1998, 188(5), 997-1001 C Gruss et al., Cytokines and Molecular Therapy 1:75-105, May 1995 D Gurley, et al., Molecular and Cellular Biology, 6:559-565, February 1986 E Habeeb, A.F.S.A., Analytical Biochemistry, 56:60-65, 1973 F Hann et al., J. Chem. Soc. Perkin Trans., I, 307-314, 1982 G Holladay et al. Tetrahedron Letters, 24(41):4401-4404, 1983	
C Gruss et al., Cytokines and Molecular Therapy 1:75-105, May 1995 D Gurley, et al., Molecular and Cellular Biology, 6:559-565, February 1986 E Habeeb, A.F.S.A., Analytical Biochemistry, 56:60-65, 1973 F Hann et al., J. Chem. Soc. Perkin Trans., 1, 307-314, 1982 G Holladay et al. Tetrahedron Letters, 24(41):4401-4404, 1983	
D Gurley, et al., Molecular and Cellular Biology, 6:559-565, February 1986 E Habeeb, A.F.S.A., Analytical Biochemistry, 56:60-65, 1973 F Hann et al., J. Chem. Soc. Perkin Trans., 1, 307-314, 1982 G Holladay et al. Tetrahedron Letters, 24(41):4401-4404, 1983	
 Habeeb, A.F.S.A., Analytical Biochemistry, 56:60-65, 1973 Hann et al., J. Chem. Soc. Perkin Trans., 1, 307-314, 1982 Holladay et al. Tetrahedron Letters, 24(41):4401-4404, 1983 	
F Hann et al., J. Chem. Soc. Perkin Trans., 1, 307-314, 1982 G Holladay et al. Tetrahedron Letters, 24(41):4401-4404, 1983	_
G Holladay et al. Tetrahedron Letters, 24(41):4401-4404, 1983	_
	_
H Houghten et al. Cell. Vol. 93, pp. 165-176, April 17, 1998	_
	_
	_
	_
	_
37, 37, 37, 37, 37, 37, 37, 37, 37, 37,	
R Kong et al., Nature, 397:315-323, 1999	
T Kozbor et al., Immunology Today, 4(3):72-79, 1983	Τ
U Lacey et al., Amer. J. of Pathology, 157(2):435-448, 2000	_
V_ Li Y.P. et al., Nature Genetics, 23:447-451, 1999	_
W Li J. et al., PNAS, 97(4):1566-1571, 2000	_
	_
	_
Z Mackett et al., Proc. Natl. Acad. Sci. USA 79:7415-7519, December 1982	_
	Ξ
	_
	_
	_
	_
	_
factor in estenciastonensis" Database Chemical Abstracts on STN No. 120:166173 Abstract	
	_
	_
J Panicali et al., Proc. Natl. Acad. Sci. USA, 79:4927-4931, August 1982	_
	_
	_
	Houghten et al., Vaccines 86, Cold Spring Harbor Laboratory, pp. 21-25, 1986 Hruby et al., Life Sciences, 31:189-199, 1982 K Hudson et al. Int. J. Protein Res., 14:177-185, 1979 L Huse, et al., Science, 246:1275-1281, December 1989 M Jennings-White et al., Tetrahedron Letters, 23(25):2533-2534, 1982 N Kamber et al., Helvetica Chimica Acta, 63(Fasc. 4):899-915, 1980 O Kobayashi et al., J. Exp. Med., Vol. 191, No. 2, 275-285 P Köhler et al., Nature, 256:495-497, 1975 O Kong et al., Nature, 397:315-323, 1999 S Kornak et al., Cell, 104:205-215, 2001 T Kozbor et al., Immunology Today, 4(3):72-79, 1983 U Lacey et al., Amer. J. of Pathology, 157(2):435-448, 2000 V Li Y.P. et al., Nature Genetics, 23:447-451, 1999 U Li J. et al., PNAS, 97(4):1566-1571, 2000 X Livingstone, David M., Methods in Enzymology, Affinity Techniques, 723-731, 1974 Logan et al., Proc. Natl. Acad. Sci. USA, 81:3655-3659, June 1984 Z Mackett et al., Proc. Natl. Acad. Sci. USA 79:7415-7519, December 1982 A Mackett et al., Journal of Virology, 49(3):857-864, March 1984 McOsker et al., J. Bone & Mineral Research, Twelfth Annual Meeting of the American Societ for Bone and Mineral Research, 5(Supp 2):S105, No. 128, Abstract, Aug. 28-31, 1990 Morley, J.S., Trends Pharm. Sci., 463-468, December 1980 Morrison et al., Proc. Natl. Acad. Sci. USA, 81:3655-16855, November 1984 Mortensen et al., J. Clinical Endrocrinology and Metabolism, 83(2):396-402, 1998 Nakagawa, N., et al., "RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogensis" Database Chemical Abstracts on STN, No. 130:166173, Abstract, Biochem. Biophys. Res. Commun., 1998, 253(2), 395-400 Neuberger et al., Nature, 312:604-608, December 1984 Nicholson et al., J. Clinical Investigation, 78:355-360, August 1986 P Anicali et al., Proc. Natl. Acad. Sci. USA, 79:4927-4931, August 1982 K Peppel et al., J. Exp. Med., 174:1483-1489, December 1991

Examiner	/Leonard Williams/ (08/28/2007)	Date
Signature	TEOGRAPH THINAITION (CONZONZOOT)	Considered

PTC/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ons are required to respond to a collection of information unless if infentious a use

Sut	stitute for form 1449/P7	ro		Complete If Known		
				Application Number	Not Yet Assigned	
11	NFORMATIC	ON DI	SCLOSURE	Filing Date	Concurrently Herewith	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Mark I. Greene	
				Art Unit	1653	
	(use as many	sheels as	necessary)	Examiner Name	A. Mohamed	
Sheet	3	of	3	Attorney Docket Number	4040/1K201US2	

	// co	Shalhoub et al., J. Cellular Biochem., 72(2):251-261,1999	_			
	CP	Sietsema et al., Drugs Exptl. Clin. Res., XV(9):389-396, 1989	+			
	CQ	Simonet et al., Cell, 89(2):309-319, 1997	 			
	CR	Singer et al., J. Clinical Endocrinology and Metabolism, 83(6):1906-1910, 1998				
CS Siris et al., J. Bone ar		Siris et al., J. Bone and Mineral Research, 13(6):1032-1038, 1998	+-			
	CT	Smith et al., Journal of Virology, 46:584-593, May 1983	 			
	CU	Spatola, A. F., Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, 7:267-357, 1983	 			
	CV	Spatola et al., Life Sciences, 38:1243-1249, 1986	 			
	CW	Suda et al., Endocrine Reviews 20(3):345-357, June 1999	†			
	CX	Suda et al., Novartis Found Symp, 232: 235, 2001 (Abstract)				
	CY	Takamatsu et al., EMBRO Journal, 6(2):307-311, 1987				
	CZ	Takasaki et al., Nature Biotechnology, 15:1266-1270, 1997				
\perp	DA	Takeda et al., Nature 314:452-454, 1985				
	DB	Tam et al., Synthesis, 955-957, December 1979				
	DC	Van Beek E., J. Bone and Mineral Research, 11(10):1492-1497, 1996				
	QD	Weitzmann et al., J. of Bone and Mineral Research, 16(2):328-337, 2001				
	DE	Williams et al., Immunology, 84:433-439, 1995				
	DF	Wong et al. Journal of Leukocyte Biology, 65:715-724, June 1999	T			
\perp	DG	Yamaguchi et al., J. of Biological Chemistry, 273(9):5177-5123, Feb. 28, 1998				
	/ DH	Yasuda et al. Proc. Natl. Acad. Sci. USA., Vol. 95 pp. 3597-3602, March 1998	1			
LY	DI	Zhang et al., Nature Biotechnology, 14:472-475, April 1996				
L/LV	V/ DJ	Zhang et al., Nature Biotechnology, 15:150-154, 1997	1			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	" 114"" (100,00,00,00)	Date	
Cinnet	Leonard Williams/ (08/28/2007)	100.0	- 1
Signature	720011a1a VVIIIIa11137 (00/20/2007)	Considered	- 1

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.